medigraphic.com
ISSN 2007-6800 (Print)

2020, Number S1

<< Back Next >>

Rev Mex Traspl 2020; 9 (S1)

Donor renal function evaluation: GFR, proteinuria, hematuria and urolithiasis. How to evaluate it? Who can become a donor?

Villca-Gonzáles R

Language: Spanish
References: 56
Page: 22-29
PDF size: 208.09 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Inker LA, Levey AS. Assessment of glomerular filtration rate. In: Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. Elsevier; 2019. pp. 29-38.

  2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375 (9731): 2073-2081.

  3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013; 1-150.

  4. Inker LA, Huang N, Levey AS. Strategies for assessing GFR and albuminuria in the living kidney donor evaluation. Curr Transplant Rep. 2017; 4 (1): 13-23.

  5. Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol. 2009; 20 (11): 2305-2313.

  6. Soveri I, Berg UB, Bjork J, Elinder CG, Grubb A, Mejare I et al. Measuring GFR: a systematic review. Am J Kidney Dis. 2014; 64 (3): 411-424.

  7. Myers GL, Miller WG, Coresh J et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem. 2006; 52 (1): 5-18.

  8. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150 (9): 604-612.

  9. Earley A, Miskulin D, Lamb EJ et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012; 156 (11): 785-795.

  10. Keddis MT, Amer H, Voskoboev N et al. Creatinine-based and cystatin C-based GFR estimating equations and their non-GFR determinants in kidney transplant recipients. Clin J Am Soc. 2016; 11 (9): 1640-1649.

  11. Eckfeldt JH, Karger AB, Miller WG, Rynders GP, Inker LA. Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS survey. Arch Pathol Lab Med. 2015; 139 (7): 888-893.

  12. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012; 367 (1): 20-29.

  13. Fan L, Inker LA, Rossert J, Froissart M, Rossing P, Mauer M et al. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrol Dial Transplant. 2014; 29 (6): 1195-1203.

  14. Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101 (8S Suppl 1): S1-S109.

  15. Andrews PA, Burnapp L. British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018: Summary of Updated Guidance. Transplantation. 2018; 102 (7): e307.

  16. Delmonico F, Council of the Transplantation Society. A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005; 79: S53-S66.

  17. European Renal Best Practice Transplantation Guideline Development Group. ERBP guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant. 2013; 28 (Suppl. 2): ii1-ii71.

  18. OPTN/UNOS. Organ Procurement & Transplantation Network Policy 14: living donation. OPTN. 2016. Disponible en: https://optn.transplant.hrsa.gov/media/1200/optn_policies. pdf

  19. Huang N, Foster MC, Lentine KL, Garg AX, Poggio ED, Kasiske BL et al. Estimated GFR for Living Kidney Donor Evaluation. Am J Transplant. 2016; 16 (1): 171-180.

  20. Gaillard F, Flamant M, Lemoine S, Baron S, Timsit MO, Eladari D et al. Estimated or measured GFR in living kidney donors work-up? Am J Transplant. 2016; 16 (10): 3024-3032.

  21. Garg AX, Muirhead N, Knoll G, Yang RC, Prasad GV, Thiessen-Philbrook H et al. Proteinuria and reduced kidney function in living kidney donors: A systematic review, meta-analysis, and meta-regression. Kidney Int. 2006; 70 (10): 1801-1810.

  22. Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015; 66 (1): 114-124.

  23. Fehrman-Ekholm I, Nordén G, Lennerling A, Rizell M, Mjörnstedt L, Wramner L et al. Incidence of end-stage renal disease among live kidney donors. Transplantation. 2006; 82 (12): 1646-1648.

  24. Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H et al. Long-term consequences of kidney donation. N Engl J Med. 2009; 360 (5): 459-469.

  25. Cherikh WS, Young CJ, Kramer BF, Taranto SE, Randall HB, Fan PY. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transplant. 2011; 11 (8): 1650-1655.

  26. Mjřen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Řyen O et al. Long-term risks for kidney donors. Kidney Int. 2014; 86 (1): 162-167.

  27. Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright J et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014; 311 (6): 579-586.

  28. Rizvi SA, Zafar MN, Jawad F, Aziz T, Hussain Z, Hashmi A et al. Long-term Safety of Living Kidney Donation in an Emerging Economy. Transplantation. 2016; 100 (6): 1284-1293.

  29. Fogazzi GB, Garigali G. Urinalysis. In: Feehally J, Floege J, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. 6th ed. Elsevier; 2019. pp. 39-52.

  30. Inker LA. Albuminuria: time to focus on accuracy. Am J Kidney Dis. 2014; 63 (3): 378-381.

  31. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl. 2005; (94): S28-S35.

  32. Grams ME, Sang Y, Levey AS et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl JMed. 2016; 374: 411-421.

  33. Mandelbrot DA, Pavlakis M, Danovitch GM et al. The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant. 2007; 7: 2333-2343.

  34. Davis R, Jones JS, Barocas DA et al. American Urological Association (AUA) guideline ADULTS: AUA guideline American Urological Association asymptomatic microhematuria. J Urol. 2012; 188 (6 Suppl): 2473-2481.

  35. Kassouf W, Aprikian A, Black P et al. Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Can Urol Assoc J. 2016; 10: E46-E80.

  36. Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med. 2003; 348: 2330-2338.

  37. Shen P, He L, Jiang Y, Wang C, Chen M. Useful indicators for performing renal biopsy in adult patients with isolated microscopic haematuria. Int J Clin Pract. 2007; 61 (5): 789-794.

  38. Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care. BMJ. 2009; 338: a3021.

  39. Hole B, Whittlestone T, Tomson C. Investigating asymptomatic invisible haematuria. BMJ. 2014; 349: g6768.

  40. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol. 2004; 24 (3): 179-196.

  41. Savige J, Rana K, Tonna S et al. Thin basement membrane nephropathy. Kidney Int. 2003; 64: 1169-1178.

  42. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic diseases in America project. Prevalence of kidney stones in the United States. Eur Urol. 2012; 62: 160-165.

  43. Boyce CJ, Pickhardt PJ, Lawrence EM, Kim DH, Bruce RJ. Prevalence of urolithiasis in asymptomatic adults: objective determination using low dose non contrast computerized tomography. J Urol. 2010; 183 (3): 1017-1021.

  44. Lorenz EC, Lieske JC, Vrtiska TJ et al. Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant. 2011; 26: 2695-2700.

  45. Olsburgh J, Thomas K, Wong K et al. Incidental renal stones in potential live kidney donors: prevalence, assessment and donation, including role of ex vivo ureteroscopy. BJU Int. 2013; 111 (5): 784-792.

  46. O’Neill DC, Davis NF, Murray TÉ, Lee MJ, Little D, Morrin MM. Prevalence of incidental findings on multidetector computed tomography in potential nephrectomy donors: a prospective observational study. Exp Clin Transplant. 2019; 17 (2): 177-182.

  47. Kim IK, Tan JC, Lapasia J, Elihu A, Busque S, Melcher ML. Incidental kidney stones: a single center experience with kidney donor selection. Clin Transplant. 2012; 26 (4): 558-563.

  48. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol. 2010; 25: 831-841.

  49. Jungers P, Joly D, Barbey F, Choukroun G, Daudon M. ESRD caused by nephrolithiasis: prevalence, mechanisms, and prevention. Am J Kidney Dis. 2004; 44: 799-805.

  50. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney stones and kidney function loss: a cohort study. BMJ. 2012; 345: e5287.

  51. El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ 3rd et al. Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol. 2012; 7 (9): 1409-1415.

  52. Gambaro G, Croppi E, Bushinsky D, Jaeger P, Cupisti A, Ticinesi A et al. The risk of chronic kidney disease associated with urolithiasis and its urological treatments: a review. J Urol. 2017; 198 (2): 268-273.

  53. Pearle MS, Goldfarb DS, Assimos DG et al. Medical management of kidney stones: AUA guideline. J Urol. 2014; 192: 316-324.

  54. Serur D, Charlton M, Juluru K et al. Long term follow up of kidney donors with asymptomatic renal stones. Nephrology. 2017; 22: 649-651.

  55. Sarier M, Duman I, Callioglu M, Soylu A, Tekin S, Turan E et al. Outcomes of conservative management of asymptomatic live donor kidney stones. Urology. 2018; 118: 43-46.

  56. Sarier M, Duman I, Yuksel Y, Tekin S, Ozer M, Yucetin L et al. Ex vivo stone surgery in donor kidneys at renal transplantation. Int J Urol. 2018; 25 (10): 844-847.




2020     |     www.medigraphic.com